Therapeutic drug monitoring of clobazam;Suivi thérapeutique pharmacologique du clobazam

Therapie

Volumn 65, Issue 3, 2010, Pages 225-231

  Bentué Ferrer, Danièle ^a   Tribut, Olivier ^a   Verdier, Marie Clémence ^a   Debruyne, Danièle ^b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CHU CÔTE DE NACRE   (France)

Author keywords

Clobazam; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; NORCLOBAZAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE;

ADD ON THERAPY; ANXIETY DISORDER; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MONITORING; EPILEPSY; FRANCE; HUMAN; PRIORITY JOURNAL; REVIEW; ADULT; AGE; ANIMAL; CHILD; COMPLICATION; DOSE RESPONSE; DRUG INTERACTION; LIVER DISEASE; METABOLISM; SEX DIFFERENCE;

ADULT; AGE FACTORS; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; EPILEPSY; HUMANS; LIVER DISEASES; SEX FACTORS;

EID: 77955741131     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2010028     Document Type: Review

References (58)

1. Hanks GW. Clobazam: pharmacological and therapeutic profile. Br J Clin Pharmacol 1979; 7 Suppl 1: 151S-155S
2. Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007; 4: 138-44
3. Brogden RN, Heel RC, Speight TM, et al. Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs 1980; 20: 161-78
4. Robertson MM. Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam. Epilepsia 1986; 27 Suppl 1: S27-41
5. Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008; 118: 69-86
6. Michael B, Marson AG. Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 2008; CD004154
7. Remy C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia 1994; 35 Suppl 5: S88-91
8. Montenegro MA, Guerreiro CA. Role of clobazam in the treatment of epilepsies. Expert Rev Neurother 2003; 3: 829-34
9. Résumé des Caractéristiques du Produit clobazam. Iditions du Vidal, 2009
10. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979; 7 Suppl 1: 51S-57S
11. Tedeschi G, Riva R, Baruzzi A. Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients. Br J Clin Pharmacol 1981; 11: 619-22
12. Pullar T, Haigh Jr, Peaker S, et al. Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. Br J Clin Pharmacol 1987; 24: 793-7
13. Jawad S, Richens A, Oxley J. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol 1984; 18: 873-7
14. Bun H, Coassolo P, Gouezo F, et al. Plasma levels and pharmacokinetics of clobazam and N-desmethylclobazam in epileptic patients. in Clobazam: Human Psychopharmacology and Clinical Applications, vol 74. Edited by Hindmarch I, Stonier P, Trimble M. London, The Royal Society of Medicine, 1985, pp 159-65
15. Divoll M, Greenblatt DJ, Ciraulo DA, et al. Clobazam kinetics: intrasubject variability and effect of food on adsorption. J Clin Pharmacol 1982; 22: 69-73
16. Kosaki K, Tamura K, Sato R, et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004; 26: 530-4
17. Contin M, Sangiorgi S, Riva R, et al. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002; 24: 737-41
18. Laux G, Koeppen D. Serum and cerebrospinal fluid concentration of clobazam and N-desmethylclobazam. Int J Clin Pharmacol Ther Toxicol 1984; 22: 355-9
19. Dulac O, Figueroa D, Rey E, et al. Monotherapy with clobazam in epilepsies in children. Presse Med 1983; 12: 1067-9
20. Kinoshita M, Ikeda A, Begum T, et al. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 2007; 263: 44-8
21. Cano JP, Bun H, Iliadis A, et al. Influence of anti-epileptic drugs on plasma levels of clobazam and desmethylclobazam: application of research on relations between doses, plasma levels and clinical efficacy. in Clobazam, vol 43. Edited by Hindmarch I, Stonier P. London, The Royal Society of Medicine, 1978, pp 169-74
22. Bardy AH, Seppala T, Salokorpi T, et al. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev 1991; 13: 174-9
23. Shimizu H, Abe J, Futagi Y, et al. Antiepileptic effects of clobazam in children. Brain Dev 1982; 4: 57-62
24. Guberman A, Couture M, Blaschuk K, et al. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci 1990; 17: 311-6
25. Callaghan N, Goggin T. Clobazam as adjunctive treatment in drug resistant epilepsy-report on an open prospective study. Ir Med J 1984; 77: 240-4
26. Goggin T, Callaghan N. Blood levels of clobazam and its metabolites and therapeutic effect. in Clobazam: Human Psychopharmacology and Clinical Applications, vol 74. Edited by Hindmarch I, Stonier P, Trimble M, The Royal Society of Medicine, 1985, pp 149-53
27. Allen JW, Oxley J, Robertson MM, et al. Clobazam as adjunctive treatment in refractory epilepsy. Br Med J (Clin Res Ed) 1983; 286: 1246-7
28. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50: 1158-66
29. Wolf P. Clobazam in drug-resistant patients with complex focal seizures-Report of an open study. in Clobazam: Human Psychopharmacology and Clinical Applications, vol 74. Edited by Hindmarch I, Stonier P, Trimble M. London, The Royal Society of Medicine, 1985, pp 167-71
30. Bun H, Monjanel-Mouterde S, Noel F, et al. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol 1990; 67: 136-40
31. Greenblatt DJ, Divoll M, Puri SK, et al. Clobazam kinetics in the elderly. Br J Clin Pharmacol 1981; 12: 631-6
32. Monjanel-Mouterde S, Antoni M, Bun H, et al. Pharmacokinetics of a single oral dose of clobazam in patients with liver disease. Pharmacol Toxicol 1994; 74: 345-50
33. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia 1998; 39: 1115-8
34. Munoz JJ, De Salamanca RE, Diaz-Obregon C, et al. The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. Br J Clin Pharmacol 1990; 29: 763-5
35. Zifkin B, Sherwin A, Andermann F. Phenytoin toxicity due to interaction with clobazam. Neurology 1991; 41: 313-4
36. Theis JG, Koren G, Daneman R, et al. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol 1997; 12: 208-13
37. Cocks A, Critchley E, Hayward H, et al. The effect of clobazam on the blood levels of sodium valproate. in Clobazam: Human Psychopharmacology and Clinical Applications, vol 74. Edited by Hindmarch I, Stonier P, Trimble M. London, The Royal Society of Medicine, 1985, pp 155-7
38. Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992; 14: 269-74
39. Levy RH, Lane EA, Guyot M, et al. Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 1983; 11: 286-92
40. Contin M, Riva R, Albani F, et al. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit 1999; 21: 604-8
41. Giraud C, Treluyer Jm, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006; 34: 608-11
42. Taeuber K, Badian M, Brettel HF, et al. Kinetic and dynamic interaction of clobazam and alcohol. Br J Clin Pharmacol 1979; 7 Suppl 1: 91S-97S
43. Pullar T, Edwards D, Haigh Jr, et al. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol 1987; 23: 317-21
44. Knapp J, Boknik P, Gumbinger HG, et al. Quantitation of clobazam in human plasma using high-performance liquid chromatography. J Chromatogr Sci 1999; 37: 145-9
45. Bolner A, Tagliaro F, Lomeo A. Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis. J Chromatogr B Biomed Sci Appl 2001; 750: 177-80
46. Tomasini Jl, Bun H, Coassolo P, et al. Determination of clobazam, N-desmethylclobazam and their hydroxy metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr 1985; 343: 369-77
47. Kunicki PK. Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis. J Chromatogr B Biomed Sci Appl 2001; 750: 41-9
48. Rouini M, Ardakani YH, Hakemi L, et al. Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 823: 167-71
49. Brachet-Liermain A, Jarry C, Faure O, et al. Liquid chromatography determination of clobazam and its major metabolite N-desmethylclobazam in human plasma. Ther Drug Monit 1982; 4: 301-5
50. Streete JM, Berry DJ, Newbery JE. The analysis of clobazam and its metabolite desmethylclobazam by high-performance liquid chromatography. Ther Drug Monit 1991; 13: 339-44
51. Dusci LJ, Hackett LP. Simultaneous determination of clobazam, N-desmethyl clobazam and clonazepam in plasma by high performance liquid chromatography. Ther Drug Monit 1987; 9: 113-6
52. Riva R, Tedeschi G, Albani F, et al. Quantitative determination of clobazam in the plasma of epileptic patients by gas-liquid chromatography with electron-capture detection. J Chromatogr 1981; 225: 219-24
53. Legatt DF, Mcintosh DP. Clobazam and norclobazam quantitation in serum by capillary gas chromatography with electron-capture detection. Clin Biochem 1993; 26: 159-63
54. Arranz Pena MI, Sanenz Lope E. Determination of clobazam and its N-demethyl metabolite in serum of epileptic patients. J Clin Chem Clin Biochem 1986; 24: 647-50
55. Nakamura M, Ohmori T, Itoh Y, et al. Simultaneous determination of benzodiazepines and their metabolites in human serum by liquid chromatography-tandem mass spectrometry using a high-resolution octadecyl silica column compatible with aqueous compounds. Biomed Chromatogr 2009; 23: 357-64
56. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-76
57. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42: 1228-55
58. Le Guellec C, Simon N, Hulot JS, et al. Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique. La Lettre du Pharmacologue 2009; 23: 21-5